Story preview
Continue reading on the publisher site for the full article.
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
13
in the last 3 days
First reported
2 days ago
12 outlets since
Countries
12 other outlets reported this story in the last 3 days.
Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in a long-term portfolio right now.
AbbVie (NYSE:ABBV) reported positive Phase 2 outcomes for zumilokibart in atopic dermatitis at EADV 2026 in Berlin. The firm said zumilokibart has been selected to progress into Phase 3 development for immune mediated skin conditions. AbbVie presented an expanded dermatology research package at EADV 2026, including…
AbbVie (ABBV) stock price today on NYSE: live quote, chart, 52-week range, volume and the latest share market news on TechGraph.